Imatinib: a selective tyrosine kinase inhibitor (Q35045448)

6 August 2017

1 reference

title

Imatinib: a selective tyrosine kinase inhibitor (English)

1 reference

6 August 2017

1 reference

Manley PW

1

1 reference

6 August 2017

Cowan-Jacob SW

2

1 reference

6 August 2017

Buchdunger E

3

1 reference

6 August 2017

Fabbro D

4

1 reference

6 August 2017

Fendrich G

5

1 reference

6 August 2017

Furet P

6

1 reference

6 August 2017

Meyer T

7

1 reference

6 August 2017

Zimmermann J

8

1 reference

6 August 2017

1 September 2002

1 reference

European Journal of Cancer

6 August 2017

1 reference

6 August 2017

38 Suppl 5

1 reference

6 August 2017

S19-27

1 reference

Oncogenic kinase signalling

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Antagonists of protein-protein interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Monoclonal antibody strategies to block angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980599-8

7 January 2021

10.1016/S0959-8049(02)80599-8

Identifiers

DOI

1 reference

release_37i6yvi5vzfffbf4qx6vgouu7e

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/37i6yvi5vzfffbf4qx6vgouu7e

24 November 2022

mapped directly with Wikidata item

1 reference